Zhu Tianyu, Chen Zhaoying, Zhang Beichen, Wu Xianqing
Department of Obstetrics and Gynecology, The Second Xiangya Hospital of Central South University, Changsha, China.
Clinical Research Center for Gynecological Disease in Hunan Province, Changsha, China.
World J Surg Oncol. 2025 May 14;23(1):187. doi: 10.1186/s12957-025-03838-7.
The identification of biomarkers that reliably forecast cervical cancer (CC) outcomes is a key area of research. Several studies have explored the link between the platelet-to-lymphocyte ratio (PLR) and cervical cancer prognosis, though the results are not entirely conclusive.
PubMed, Embase, Web of Science, and the Cochrane Library were used to search, with studies published up to May 30, 2024. The selection of studies followed predetermined inclusion and exclusion criteria. Overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) were primary outcomes. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses were performed to evaluate the stability and investigate potential heterogeneity. Review Manager version 5.4.1 and STATA version 15.0 were conducted to analyze.
Thirty cohort studies, involving 8,597 patients, were included. The pooled data showed that a higher PLR was associated with worse OS significantly (HR = 1.77, 95% CI: 1.43-2.19; p < 0.0001), PFS (HR = 1.69, 95% CI: 1.26-2.27; p = 0.0004), and DFS (HR = 1.57, 95% CI: 1.12-2.18; p = 0.008). Subgroup analysis indicated that the prognostic relevance of PLR was most prominent in patients who underwent both surgery and radiotherapy, as well as those from Asia and the America. Furthermore, a PLR threshold above 150 was associated with improved predictive accuracy.
Increased PLR among cervical cancer patients was significantly correlated with reduced OS, PFS, and DFS, pointing to its potential role as an independent prognostic marker. Nonetheless, additional prospective research is required to verify this finding.
确定能够可靠预测宫颈癌（CC）预后的生物标志物是一个关键研究领域。多项研究探讨了血小板与淋巴细胞比值（PLR）与宫颈癌预后之间的联系，但其结果并不完全确凿。
利用PubMed、Embase、Web of Science和Cochrane图书馆进行检索，纳入截至2024年5月30日发表的研究。研究的选择遵循预先确定的纳入和排除标准。总生存期（OS）、无进展生存期（PFS）和无病生存期（DFS）为主要结局指标。计算风险比（HR）和95%置信区间（CI）。进行敏感性和亚组分析以评估稳定性并调查潜在的异质性。使用Review Manager 5.4.1版和STATA 15.0版进行分析。
纳入30项队列研究，涉及8597例患者。汇总数据显示，较高的PLR与较差的OS（HR = 1.77，95% CI：1.43 - 2.19；p < 0.0001）、PFS（HR = 1.69，95% CI：1.26 - 2.27；p = 0.0004）和DFS（HR = 1.57，95% CI：1.12 - 2.18；p = 0.008）显著相关。亚组分析表明，PLR的预后相关性在接受手术和放疗的患者以及来自亚洲和美洲的患者中最为突出。此外，PLR阈值高于150与预测准确性提高相关。
宫颈癌患者PLR升高与OS、PFS和DFS降低显著相关，表明其作为独立预后标志物的潜在作用。尽管如此，仍需要更多的前瞻性研究来验证这一发现。
